Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197252 | 0.85 | CYP1A2 (0.50) | AKR1C3AKR1C2CYP1A2HTTTP53 | |
| SCHEMBL31248053 | 0.85 | CYP1A2 (0.50) | AKR1C3AKR1C2CYP1A2HTTTP53 | |
| SCHEMBL1640118 | 0.84 | AKR1C3 (0.55) | AKR1C3AKR1C2CYP1A2HTTTP53 | |
| SCHEMBL9070339 | 0.84 | TDP1 (0.51) | AKR1C3AKR1C2HTTTP53ALDH1A1 | |
| SCHEMBL4658229 | 0.84 | AKR1C3 (0.46) | AKR1C3AKR1C2HTTTP53POLB | |
| SCHEMBL1640119 | 0.84 | AKR1C3 (0.55) | AKR1C3AKR1C2CYP1A2HTTTP53 | |
| SCHEMBL4369639 | 0.82 | GAA (0.50) | AKR1C3AKR1C2HTTTP53POLB | |
| SCHEMBL4658986 | 0.82 | ALDH1A1 (0.49) | AKR1C3AKR1C2HTTTP53POLB | |
| SCHEMBL4369630 | 0.82 | GAA (0.50) | AKR1C3AKR1C2HTTTP53POLB | |
| SCHEMBL4658268 | 0.81 | LMNA (0.48) | AKR1C3AKR1C2POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507410-B2 | Pyridazinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8470738-B2 | Pyridazinone compound and herbicide containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2406232-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2188264-B1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | SUMITOMO CHEMICAL CO (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010104217-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20100216642-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | C5, C1S, WEE1 | AKR1C3 107/4885AKR1C2 534/4885CYP1A2 56/4885 |
| US-20100216642-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | WEE1, WEE2, CBR3 | AKR1C3 103/4885AKR1C2 149/4885CYP1A2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.